Research
Hormonal
Dual GIP/GLP-1 receptor agonists (tirzepatide) demonstrate enhanced efficacy compared to single GLP-1 agonists, likely due to synergistic modulation of GIP and GLP-1 pathways.
Tirzepatide is a dual-acting drug (GIP and GLP-1) that is more effective than single-acting GLP-1 drugs like semaglutide. It is taken once weekly. You will likely experience gastrointestinal side effects initially, which usually improve over time.
GoodSupportsHIGH confidence
Dual agonists, particularly tirzepatide, show enhanced efficacy, likely due to synergistic modulation of GIP and GLP-1 pathways.
Why this rating
Based on SURMOUNT-1 Phase 3 RCT.
Source
INCRETIN-BASED PHARMACOTHERAPY FOR OBESITY: A COMPARATIVE NARRATIVE REVIEW OF GLP-1, DUAL AND TRIPLE AGONISTS AND COMBINATION THERAPIES
Łukasz Krzystek et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.4(48).2025.4388
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Triple receptor agonists (retatrutide) produce the highest magnitude of weight loss reported to date in pharmacotherapy for obesity, surpassing dual and single GLP-1 agonists.Good
- Combination therapy of semaglutide and cagrilintide (CagriSema) produces weight loss comparable to multi-receptor agonists by targeting complementary metabolic pathways.Good
- GLP-1 receptor agonists (liraglutide, semaglutide) reduce body weight and improve metabolic parameters by modulating central appetite pathways and delaying gastric emptying.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →